Proton therapy in young breast cancer patients with germline TP53 and ATM mutations: a case series.

Intensity-modulated proton therapy (IMPT) — healthy tissue dose reduction to limit toxicities and radiation-induced malignancies in germline TP53/ATM carriers

This single-center case series (Institut Curie) includes young patients with non-metastatic breast cancer and germline TP53 or ATM mutations treated with intensity-modulated proton therapy between 2019 and 2024. Acute and late toxicity profiles are analyzed. IMPT allows significant dosimetric reduction of organs at risk — heart, contralateral lung, contralateral breast — particularly critical in TP53 carriers due to radiation-induced cancer risk.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Proton therapy remains limited in accessibility, but these Institut Curie data are important: they document feasibility and tolerability in germline TP53/ATM carriers, for whom conventional radiotherapy poses a real radiation-induced risk problem. A series to keep on hand for tumor board discussions involving Li-Fraumeni carriers.

Clinical impact: 2/3 · Evidence strength: 1/3 · Novelty: 2/2 · Sample size: 0/1 · Publication status: 0/1 → Total: 5/10